Searchable abstracts of presentations at key conferences in endocrinology

ea0081p326 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Personalized glycemic response based Diabefly-Pro® digital therapeutics improves dietary patterns, glycemic control and reduces postprandial hyperglycemia in real-world settings

Joshi Shilpa , Verma Ritika , Khader Mohammed , Nikte Sneha , Ade Suresh , Bandukwala Saifuddin , Joshi Mitali , Methil Vinod , Tiwaskar Mangesh , Singal Arbinder

Background: CGM based monitoring can help in development of personalized digital therapeutics programs based on the understanding of the effect of diet, physical activity and medications on everyday blood glucose excursions. The variation in intra-individual glycemic response to the same food has been reported in many studies. Thus, understanding of personalized glycemic response (PGR) of each individual becomes important for effective diabetes management.<p class="abstext...

ea0073aep264 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Treatment recommendations for dapagliflozin across a cardio-renal and viscero metabolic (crv-m) continuum: an expert consensus delphi study

Das Ashok , Awasthi Rajeev , Sahay Manisha , Sahoo Abhay , Hazra Prakash , Kapoor Nitin , Tiwaskar Mangesh , Bhandarkar Prashant , Sahay Rakesh , Bhattacharya Saptarshi , Saboo Banshi , Pandit Kaushik , Kishor Kamal , Marwah Tiven , Agrawal Navneet , Sharma Kamal , Khanna Umesh , Bantwal Ganapathi , Joshi Ameya , Kerkar Prafulla , Kalra Sanjay

IntroductionDapagliflozin is sub-optimally utilised in the real world. There is a lack of a comprehensive collaborative guidance for a practical approach to manage patients with cardiometabolic, renometabolic and viscerometabolic disorders. Patients across the CRV-M continuum includes patients with varied clinical profiles.MethodsTwo round Delphi study was conducted using a virtual online-digital connect appr...